1. Home
  2. DHY vs AMRN Comparison

DHY vs AMRN Comparison

Compare DHY & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DHY
  • AMRN
  • Stock Information
  • Founded
  • DHY 1998
  • AMRN 1989
  • Country
  • DHY United States
  • AMRN Ireland
  • Employees
  • DHY N/A
  • AMRN N/A
  • Industry
  • DHY Finance/Investors Services
  • AMRN Biotechnology: Pharmaceutical Preparations
  • Sector
  • DHY Finance
  • AMRN Health Care
  • Exchange
  • DHY Nasdaq
  • AMRN Nasdaq
  • Market Cap
  • DHY 224.6M
  • AMRN 189.2M
  • IPO Year
  • DHY N/A
  • AMRN 1993
  • Fundamental
  • Price
  • DHY $2.13
  • AMRN $0.57
  • Analyst Decision
  • DHY
  • AMRN Buy
  • Analyst Count
  • DHY 0
  • AMRN 1
  • Target Price
  • DHY N/A
  • AMRN N/A
  • AVG Volume (30 Days)
  • DHY 569.1K
  • AMRN 1.7M
  • Earning Date
  • DHY 01-01-0001
  • AMRN 02-27-2025
  • Dividend Yield
  • DHY 9.10%
  • AMRN N/A
  • EPS Growth
  • DHY N/A
  • AMRN N/A
  • EPS
  • DHY N/A
  • AMRN N/A
  • Revenue
  • DHY N/A
  • AMRN $241,021,000.00
  • Revenue This Year
  • DHY N/A
  • AMRN N/A
  • Revenue Next Year
  • DHY N/A
  • AMRN N/A
  • P/E Ratio
  • DHY N/A
  • AMRN N/A
  • Revenue Growth
  • DHY N/A
  • AMRN N/A
  • 52 Week Low
  • DHY $1.77
  • AMRN $0.43
  • 52 Week High
  • DHY $2.08
  • AMRN $1.37
  • Technical
  • Relative Strength Index (RSI)
  • DHY 43.29
  • AMRN 62.67
  • Support Level
  • DHY $2.10
  • AMRN $0.43
  • Resistance Level
  • DHY $2.19
  • AMRN $0.49
  • Average True Range (ATR)
  • DHY 0.03
  • AMRN 0.04
  • MACD
  • DHY -0.00
  • AMRN 0.01
  • Stochastic Oscillator
  • DHY 37.50
  • AMRN 99.71

About DHY Credit Suisse High Yield Bond Fund

Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company with the objective to seek high current income and capital appreciation as a secondary objective.

About AMRN Amarin Corporation plc

Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.

Share on Social Networks: